AU2001277781A1 - Stabilized antibody-containing preparations - Google Patents

Stabilized antibody-containing preparations

Info

Publication number
AU2001277781A1
AU2001277781A1 AU2001277781A AU7778101A AU2001277781A1 AU 2001277781 A1 AU2001277781 A1 AU 2001277781A1 AU 2001277781 A AU2001277781 A AU 2001277781A AU 7778101 A AU7778101 A AU 7778101A AU 2001277781 A1 AU2001277781 A1 AU 2001277781A1
Authority
AU
Australia
Prior art keywords
containing preparations
stabilized antibody
antibody
stabilized
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001277781A
Inventor
Tsutomu Arakawa
Akira Hayasaka
Yoshiki Hayashi
Masaya Kakuta
Tadao Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26918882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001277781(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2001277781A1 publication Critical patent/AU2001277781A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2001277781A 2000-08-11 2001-08-13 Stabilized antibody-containing preparations Abandoned AU2001277781A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22483400P 2000-08-11 2000-08-11
US22462300P 2000-08-11 2000-08-11
US60224623 2000-08-11
US60224834 2000-08-11
PCT/JP2001/006978 WO2002013860A1 (en) 2000-08-11 2001-08-13 Stabilized antibody-containing preparations

Publications (1)

Publication Number Publication Date
AU2001277781A1 true AU2001277781A1 (en) 2002-02-25

Family

ID=26918882

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001277781A Abandoned AU2001277781A1 (en) 2000-08-11 2001-08-13 Stabilized antibody-containing preparations

Country Status (8)

Country Link
US (1) US8632778B2 (en)
EP (2) EP1314437B1 (en)
JP (2) JP5485489B2 (en)
AU (1) AU2001277781A1 (en)
DK (1) DK1314437T3 (en)
ES (2) ES2644275T3 (en)
PT (1) PT1314437E (en)
WO (1) WO2002013860A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008243208B2 (en) * 2002-02-14 2011-05-19 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE547119T1 (en) 1997-03-21 2012-03-15 Chugai Pharmaceutical Co Ltd PREVENTIVE OR THERAPEUTIC AGENT CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENTS FOR SENSITIZED T CELL-MEDIATED DISEASES
ES2571230T3 (en) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedure to control the activity of an immunofunctional molecule
JP4147234B2 (en) 2004-09-27 2008-09-10 キヤノン株式会社 Discharge liquid, discharge method, cartridge, and discharge device
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP1946776B1 (en) * 2002-02-27 2017-01-18 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
ATE402716T1 (en) * 2002-02-27 2008-08-15 Immunex Corp STABILIZED TNFR-FC FORMULATION WITH ARGININE
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
AU2013201261B2 (en) * 2002-06-14 2016-06-23 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
AU2011226771B2 (en) * 2002-06-14 2012-10-04 Medimmune, Llc Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20060182740A1 (en) * 2002-06-21 2006-08-17 Biogen Idec, Inc. Buffered formulations for concentrating antibodies and methods of use thereof
JP2006502116A (en) * 2002-07-12 2006-01-19 メダレックス， インク． Methods and compositions for preventing oxidative degradation of proteins
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CN100522989C (en) 2002-09-11 2009-08-05 中外制药株式会社 Method of purifying protein
DE60324700D1 (en) * 2002-10-11 2008-12-24 Chugai Pharmaceutical Co Ltd CELL TOD INDUCTIVE ACTIVE SUBSTANCE
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP1589996A4 (en) * 2003-01-30 2009-01-21 Medimmune Inc Anti-integrin alpha beta 3 antibody formulat ions and uses thereof
FR2853551B1 (en) * 2003-04-09 2006-08-04 Lab Francais Du Fractionnement STABILIZING FORMULATION FOR IMMUNOGLOBULIN G COMPOSITIONS IN LIQUID FORM AND LYOPHILIZED FORM
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
EP1698640B2 (en) 2003-10-01 2019-06-19 Kyowa Hakko Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
WO2005056605A1 (en) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha Modified antibodies recognizing trimer receptor or higher
EP3269738A1 (en) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
US20080274110A1 (en) * 2004-04-09 2008-11-06 Shuji Ozaki Cell Death-Inducing Agents
JP4879884B2 (en) * 2004-04-12 2012-02-22 メディミューン，エルエルシー Anti-IL-9 antibody preparation and use thereof
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP4147235B2 (en) 2004-09-27 2008-09-10 キヤノン株式会社 Discharge liquid, discharge method, droplet forming method, liquid discharge cartridge, and discharge apparatus
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
AR053026A1 (en) * 2005-03-08 2007-04-18 Pharmacia & Upjohn Co Llc COMPOSITIONS OF ANTIBODIES ANTI FACTOR OF STIMULATION OF COLONIES OF MACROFAGOS (ANTI-M CSF)
EP1870458B1 (en) * 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
JO3058B1 (en) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc Anti-IL-6 Antibodies,Compositions,Methods and uses
TW200718780A (en) * 2005-06-10 2007-05-16 Chugai Pharmaceutical Co Ltd Sc(Fv)2 site-directed mutant
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN101262885B (en) * 2005-06-10 2015-04-01 中外制药株式会社 Pharmaceutical compositions containing sc(Fv)2
BRPI0611901A2 (en) 2005-06-14 2012-08-28 Amgen, Inc composition, lyophilized kit and process for preparing a composition
US20060286103A1 (en) 2005-06-15 2006-12-21 Parag Kolhe Stable antibody formulation
US20070110757A1 (en) * 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
EP1899462B1 (en) * 2005-07-02 2011-03-09 Arecor Limited Stable aqueous systems comprising proteins
GB0610140D0 (en) * 2006-05-22 2006-06-28 Insense Ltd Protein stability
EA014513B1 (en) 2005-08-03 2010-12-30 Иммьюноджен, Инк. Immunoconjugate formulations
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
JPWO2008007755A1 (en) * 2006-07-13 2009-12-10 中外製薬株式会社 Cell death inducer
AU2007272412B2 (en) * 2006-07-14 2013-11-07 Genentech, Inc. Refolding of recombinant proteins
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US20080177614A1 (en) * 2007-01-24 2008-07-24 Lianjun An Method and system for estimating dynamics of workforce absenteeism using information on pandemic spread and mitigation actions
US7746769B2 (en) * 2007-03-26 2010-06-29 Alcatel Lucent Management of redundant and multi-segment pseudo-wire
KR20100014674A (en) 2007-03-29 2010-02-10 아보트 러보러터리즈 Crystalline anti-human il-12 antibodies
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
US20090181027A1 (en) * 2007-09-28 2009-07-16 Paul Dal Monte Anti-IL-12/23p40 Antibodies, Epitopes, Formulations, Compositions, Methods and Uses
US20130195888A1 (en) * 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
CN101969971A (en) * 2007-11-30 2011-02-09 雅培制药有限公司 Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
EP3936116A1 (en) 2007-12-28 2022-01-12 Takeda Pharmaceutical Company Limited Rrecombinant vwf containing formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
WO2009129226A1 (en) 2008-04-15 2009-10-22 Talecris Biotherapeutics, Inc. Two-stage ultrafiltration/diafiltration
ES2519475T5 (en) 2008-05-01 2018-07-02 Arecor Limited Formulation of a protein
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
PT2349314E (en) 2008-10-21 2013-05-28 Baxter Int Lyophilized recombinant vwf formulations
CA2737045C (en) * 2008-11-20 2017-11-14 Bruce Kabakoff Therapeutic protein formulations
US9056896B2 (en) 2009-03-27 2015-06-16 Asahi Kasei Medical Co., Ltd. Method for removing viruses from high concentration monoclonal antibody solution
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
SI3202785T1 (en) 2009-10-26 2024-08-30 F. Hoffmann-La Roche Ag Method for the production of a glycosylated immunoglobulin
KR101333276B1 (en) 2009-11-20 2013-11-27 센트로 데 인무노로지아 몰레큘라 Formulations of antibody
JO3417B1 (en) * 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
RS61082B1 (en) 2010-02-26 2020-12-31 Novo Nordisk As Stable antibody containing compositions
EP2542257B1 (en) 2010-03-01 2017-07-05 Bayer Healthcare LLC Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2568960B1 (en) 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
RU2012153786A (en) 2010-05-28 2014-07-10 Ново Нордиск А/С STABLE MULTI-DOSE COMPOSITIONS CONTAINING ANTIBODY AND CONSERVANT
AU2015249186B2 (en) * 2010-09-17 2018-03-22 Baxalta GmbH Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutal ph
CN103282042B (en) * 2010-09-17 2014-12-10 巴克斯特国际公司 Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
SG189220A1 (en) 2010-10-06 2013-05-31 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
WO2012064627A2 (en) 2010-11-08 2012-05-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody
CN105854016A (en) 2010-11-11 2016-08-17 艾伯维生物技术有限公司 Improved high concentration anti-TNF[alpha] antibody liquid formulations
US9453067B2 (en) 2011-04-20 2016-09-27 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Compositions for the treatment of rheumatoid arthritis and methods of using same
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
TW201325606A (en) 2011-10-18 2013-07-01 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
EP2771033A4 (en) 2011-10-28 2016-02-17 Integritybio Inc Protein formulations containing amino acids
AU2013212587B2 (en) 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
CA2873647A1 (en) 2012-05-14 2013-11-21 Ole Elvang Jensen Stabilised protein solutions
RU2711089C2 (en) 2012-05-18 2020-01-15 Дженентек, Инк. Highly concentrated compositions of monoclonal antibodies
AR092325A1 (en) 2012-05-31 2015-04-15 Regeneron Pharma STABILIZED FORMULATIONS CONTAINING ANTI-DLL4 ANTIBODIES AND KIT
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EA201791717A1 (en) 2012-09-07 2018-03-30 Кохерус Байосайенсис, Инк. STABLE WATER COMPOSITIONS ADALIMUMAB
CA2882551A1 (en) 2012-09-11 2014-03-20 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
JP6411891B2 (en) * 2012-10-03 2018-10-24 協和発酵キリン株式会社 Method for preventing reduction of polypeptide by adding amino acid to culture medium
RU2674996C2 (en) 2013-07-04 2018-12-14 Ф. Хоффманн-Ля Рош Аг Immunoassay method with interference suppression for determination of antibodies for drugs in serum samples
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US10688187B2 (en) 2014-04-02 2020-06-23 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
CA2973423C (en) * 2015-02-09 2023-09-05 Ucb Biopharma Sprl Pharmaceutical formulation
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
CN109862880A (en) 2016-09-27 2019-06-07 德国费森尤斯卡比有限公司 Composition of liquid medicine
CN114917185B (en) 2016-10-21 2023-11-14 美国安进公司 Pharmaceutical formulations and methods of making the same
ES2882181T3 (en) 2016-10-31 2021-12-01 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
EP3570882B1 (en) * 2017-01-19 2021-11-17 Bayer Pharma Aktiengesellschaft Novel stable formulation for fxia antibodies
TW201834639A (en) * 2017-03-06 2018-10-01 德商馬克專利公司 Aqueous antibody formulation
EP3596175A4 (en) 2017-03-17 2021-01-13 The Ohio State Innovation Foundation Nanoparticles for delivery of chemopreventive agents
MX2020005630A (en) * 2017-11-30 2020-08-20 Bio Thera Solutions Ltd Liquid preparation of humanized antibody for treating il-6-related disease.
JP6903617B2 (en) * 2018-09-19 2021-07-14 株式会社東芝 How to determine the molecular probe
CN114206442A (en) 2019-01-31 2022-03-18 赛诺菲生物技术公司 anti-IL-6 receptor antibodies for the treatment of juvenile idiopathic arthritis
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360457A (en) 1979-08-30 1982-11-23 Teijin Limited S-Sulfonated immunoglobulin composition having a high monomer content and a process for production thereof
JPS5657718A (en) * 1979-10-17 1981-05-20 Teijin Ltd Preparation of s-sulfonated immunoglobulin containing large amount of monomer
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
JPS5731623A (en) * 1980-07-30 1982-02-20 Morishita Seiyaku Kk Production of gamma-globulin for intravenous injection
JP2648301B2 (en) 1983-12-27 1997-08-27 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド Vector containing auxiliary DNA for transformation of eukaryotic cells
JPS61159167A (en) 1984-12-29 1986-07-18 Nitto Electric Ind Co Ltd Immunological reagent for diagnosis
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
DE3729863A1 (en) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh STABILIZED ERYTHROPOIETIN LYOPHILISATES
WO1990006764A1 (en) 1988-12-15 1990-06-28 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
US4933435A (en) 1989-04-05 1990-06-12 Bioprobe International Antibody purification process
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
ATE144713T1 (en) 1989-07-20 1996-11-15 Tadamitsu Kishimoto ANTIBODIES TO HUMAN INTERLEUKIN-6 RECEPTOR
IT1240314B (en) * 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. STABILIZED AQUEOUS FORMULATIONS OF SMALL PEPTIDES.
KR100263845B1 (en) 1989-10-13 2000-08-16 스튜어트 엘.왓트 Erythropoietin isoforms and preparation method thereof and pharmaceutical composition containing it
EP0460607A3 (en) * 1990-06-05 1992-04-01 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors
CA2052283A1 (en) 1990-09-27 1992-03-28 Edgar Haber Recombinant hybrid immunoglobulin molecules and method of use
DK0628639T3 (en) 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Reconstituted human antibody to human interleukin-6 receptor
JP2966592B2 (en) 1991-07-20 1999-10-25 萩原 義秀 Stabilized human monoclonal antibody preparation
ES2291264T3 (en) 1991-12-20 2008-03-01 Novo Nordisk A/S STABILIZED PHARMACEUTICAL FORMULATION UNDERSTANDING A GROWTH AND HISTIDINE HORMONE.
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
JP3630453B2 (en) * 1994-09-30 2005-03-16 中外製薬株式会社 A therapeutic agent for immature myeloma cells comprising an IL-6 receptor antibody as an active ingredient
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
SI2275119T1 (en) 1995-07-27 2013-12-31 Genentech, Inc. Stable isotonic lyophilized protein formulation
HUP9904177A3 (en) 1996-09-26 2001-10-29 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
EP0852951A1 (en) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
ES2190087T3 (en) 1997-06-13 2003-07-16 Genentech Inc STABILIZED FORMULATION OF AN ANTIBODY.
ATE512225T1 (en) 1998-04-03 2011-06-15 Chugai Pharmaceutical Co Ltd HUMANIZED ANTIBODY AGAINST HUMAN TISSUE FACTOR (TF) AND METHOD FOR CONSTRUCTING SUCH HUMANIZED ANTIBODY.
SI1150712T1 (en) 1999-02-05 2009-02-28 Merck & Co Inc Human papilloma virus vaccine formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008243208B2 (en) * 2002-02-14 2011-05-19 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations

Also Published As

Publication number Publication date
DK1314437T3 (en) 2014-07-14
EP2311492A1 (en) 2011-04-20
ES2644275T3 (en) 2017-11-28
ES2477996T3 (en) 2014-07-18
JP5562926B2 (en) 2014-07-30
PT1314437E (en) 2014-08-29
EP1314437A4 (en) 2008-10-15
EP1314437B1 (en) 2014-06-25
US8632778B2 (en) 2014-01-21
WO2002013860A1 (en) 2002-02-21
JP2012072173A (en) 2012-04-12
US20030190316A1 (en) 2003-10-09
EP2311492B1 (en) 2017-10-04
EP1314437A1 (en) 2003-05-28
JP5485489B2 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
AU2001277781A1 (en) Stabilized antibody-containing preparations
AU2001236005A1 (en) Preparations stabilized over long time
AU2001294192A1 (en) Solid preparations
AU2001276737A1 (en) Protein injection preparations
AU2001234125A1 (en) Antibody library
AU2001282617A1 (en) Compositions for external preparations
AU2001282607A1 (en) Solution preparations stabilized over long time
AU3942901A (en) Navigational aid
AU8260701A (en) Solution preparations stabilized over long time
AU2002236477A1 (en) Fgf-affinity chromatography
AU2001284418A1 (en) Novel polypeptide
AU2001242479A1 (en) Proliposomal encapsulated preparations
AU2001240791A1 (en) Sequence
AU2002358142A1 (en) Low-dust solid fuel preparations
AU2001288102A1 (en) Solid preparations
AU2001272427A1 (en) Solid preparations
AU2002221132A1 (en) Novel antibody
AU2001282521A1 (en) OCT preparations
AU2001244863A1 (en) Apoptin-associating protein
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU2001236058A1 (en) Preparations for chondrogenesis
AU2001278975A1 (en) Alpha-conotoxin peptides
AU2001284272A1 (en) Kinase d interacting protein
AU2001295042A1 (en) Anti-stilbene antibodies
AU2001241044A1 (en) Mitf-associated proteins